Sagittarius Life Science Asset Resilience Ratio
Sagittarius Life Science asset resilience ratio. Sagittarius Life Science (3205) has an Asset Resilience Ratio of 60.84% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Sagittarius Life Science to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sagittarius Life Science (2016–2025)
Asset resilience ratio of Sagittarius Life Science from 2016 to 2025. This chart shows how Sagittarius Life Science's Asset Resilience Ratio has changed over time. Read total liabilities of Sagittarius Life Science for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sagittarius Life Science's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 3205 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$652.00 Million | 60.84% |
| Total Liquid Assets | NT$652.00 Million | 60.84% |
Asset Resilience Insights
- Very High Liquidity: Sagittarius Life Science maintains exceptional liquid asset reserves at 60.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sagittarius Life Science Industry Peers by Asset Resilience Ratio
Compare Sagittarius Life Science's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Sagittarius Life Science Asset Resilience Ratio by Year (2016–2025)
Sagittarius Life Science asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Sagittarius Life Science.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.84% | NT$652.00 Million ≈ $20.54 Million |
NT$1.07 Billion ≈ $33.76 Million |
+46.00pp |
| 2024-12-31 | 14.83% | NT$77.11 Million ≈ $2.43 Million |
NT$519.83 Million ≈ $16.38 Million |
+2.57pp |
| 2023-12-31 | 12.26% | NT$81.49 Million ≈ $2.57 Million |
NT$664.72 Million ≈ $20.94 Million |
-1.60pp |
| 2022-12-31 | 13.86% | NT$80.24 Million ≈ $2.53 Million |
NT$579.12 Million ≈ $18.25 Million |
-1.42pp |
| 2021-12-31 | 15.28% | NT$103.25 Million ≈ $3.25 Million |
NT$675.75 Million ≈ $21.29 Million |
+14.45pp |
| 2020-12-31 | 0.83% | NT$6.15 Million ≈ $193.76K |
NT$740.74 Million ≈ $23.34 Million |
+0.34pp |
| 2019-12-31 | 0.49% | NT$4.00 Million ≈ $126.02K |
NT$811.59 Million ≈ $25.57 Million |
-8.32pp |
| 2016-12-31 | 8.81% | NT$124.50 Million ≈ $3.92 Million |
NT$1.41 Billion ≈ $44.50 Million |
-- |
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.